Dataset from A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

The aim of this study is to learn more about the following treatment options in adults with
CIDP:

- Subcutaneous self-infusion with HyQvia.

- Intravenous infusion with Gammagard/Kiovig. Gammagard and Kiovig are the brand names for
the same immunoglobulin compound.

The study is in two parts. In Part 1, participants receive either HyQvia or a placebo
subcutaneously. In Part 2 (only for participants who have a CIPD relapse during Part 1),
participants will receive Gammagard Liquid/Kiovig intravenously. US participants will receive
Gamunex-C.

The first SC infusion will be given in the study clinic. The remaining SC infusions may be
given in the study clinic or the participant's home. This will be decided by the study doctor
and whether the participant or their caregiver can do the self-infusion.